Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 6/20 | 0.43 |
| ▸ | TNF | P01375 | 2/20 | 0.41 |
| ▸ | MDM4 | O15151 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2605150 | 0.92 | TLR2 (0.44) | TLR2TNFMDM4TP53KMT2A | |
| SCHEMBL2605152 | 0.80 | TNF (0.47) | TLR2TNFHDAC1HDAC2 | |
| SCHEMBL15281659 | 0.78 | CNR2 (0.50) | KMT2A | |
| SCHEMBL1594038 | 0.77 | KMT2A (0.43) | MDM4TP53KMT2ACASP3 | |
| SCHEMBL16588596 | 0.75 | MEN1 (0.42) | KMT2A | |
| SCHEMBL16588609 | 0.75 | MEN1 (0.43) | KMT2A | |
| SCHEMBL19827331 | 0.75 | MEN1 (0.53) | KMT2A | |
| SCHEMBL12632771 | 0.75 | MEN1 (0.53) | KMT2A | |
| SCHEMBL15281661 | 0.75 | MEN1 (0.53) | KMT2A | |
| SCHEMBL344460 | 0.74 | CASP3 (0.48) | MDM4TP53KMT2ACASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163705-B2 | Glycolipid and use thereof | RIKEN (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20090221516-A1 | NOVEL GLYCOLIPID AND USE THEREOF | RIKEN (JP) | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221516-A1 | NOVEL GLYCOLIPID AND USE THEREOF | IL4, IL2, IL5 | TLR2 67/4885TNF 87/4885MDM4 4011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.